151 related articles for article (PubMed ID: 33880760)
61. Effects of Rifamycin Coadministration on Bedaquiline Desmethylation in Healthy Adult Volunteers.
Healan AM; Salata RA; Griffiss JM; Proskin HM; O'Riordan MA; Gray WA; Blumer JL
Clin Pharmacol Drug Dev; 2019 May; 8(4):436-442. PubMed ID: 30500116
[TBL] [Abstract][Full Text] [Related]
62. Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin.
Hoch M; Hoever P; Theodor R; Dingemanse J
Eur J Clin Pharmacol; 2013 Jun; 69(6):1235-45. PubMed ID: 23334403
[TBL] [Abstract][Full Text] [Related]
63. Enantiospecific Pharmacogenomics of Fluvastatin.
Hirvensalo P; Tornio A; Neuvonen M; Kiander W; Kidron H; Paile-Hyvärinen M; Tapaninen T; Backman JT; Niemi M
Clin Pharmacol Ther; 2019 Sep; 106(3):668-680. PubMed ID: 30989645
[TBL] [Abstract][Full Text] [Related]
64. Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
Noh YH; Lim HS; Jin SJ; Kim MJ; Kim YH; Sung HR; Choi HY; Bae KS
Clin Ther; 2012 May; 34(5):1182-94. PubMed ID: 22534255
[TBL] [Abstract][Full Text] [Related]
65. Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin.
Kivistö KT; Villikka K; Nyman L; Anttila M; Neuvonen PJ
Clin Pharmacol Ther; 1998 Dec; 64(6):648-54. PubMed ID: 9871429
[TBL] [Abstract][Full Text] [Related]
66. Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients.
Holdaas H; Hagen E; Asberg A; Lund K; Hartman A; Vaidyanathan S; Prasad P; He YL; Yeh CM; Bigler H; Rouilly M; Denouel J
Int J Clin Pharmacol Ther; 2006 Apr; 44(4):163-71. PubMed ID: 16625985
[TBL] [Abstract][Full Text] [Related]
67. Rifampin, a cytochrome P450 3A inducer, decreases plasma concentrations of antipsychotic risperidone in healthy volunteers.
Mahatthanatrakul W; Nontaput T; Ridtitid W; Wongnawa M; Sunbhanich M
J Clin Pharm Ther; 2007 Apr; 32(2):161-7. PubMed ID: 17381666
[TBL] [Abstract][Full Text] [Related]
68. Effects of single nucleotide polymorphisms and haplotypes of the SLCO1B1 gene on the pharmacokinetic profile of atorvastatin in healthy Macedonian volunteers.
Daka A; Dimovski A; Kapedanovska A; Vavlukis M; Eftimov A; Labachevski N; Jakjovski K; Geshkovska MN; Nebija D; Mladenovska K
Pharmazie; 2015 Jul; 70(7):480-8. PubMed ID: 26373210
[TBL] [Abstract][Full Text] [Related]
69. Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
Wrishko RE; McCrea JB; Yee KL; Liu W; Panebianco D; Mangin E; Chakravarthy M; Martinez-Cantarin MP; Kraft WK
Clin Drug Investig; 2019 May; 39(5):441-451. PubMed ID: 30810914
[TBL] [Abstract][Full Text] [Related]
70. Lack of interaction between fluvastatin and oral hypoglycemic agents in healthy subjects and in patients with non-insulin-dependent diabetes mellitus.
Appel S; Rüfenacht T; Kalafsky G; Tetzloff W; Kallay Z; Hitzenberger G; Kutz K
Am J Cardiol; 1995 Jul; 76(2):29A-32A. PubMed ID: 7604792
[TBL] [Abstract][Full Text] [Related]
71. Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin.
Kivistö KT; Kantola T; Neuvonen PJ
Br J Clin Pharmacol; 1998 Jul; 46(1):49-53. PubMed ID: 9690949
[TBL] [Abstract][Full Text] [Related]
72. Time-of-intake (morning versus evening) of extended-release fluvastatin in hyperlipemic patients is without influence on the pharmacodynamics (mevalonic acid excretion) and pharmacokinetics.
Fauler G; Abletshauser C; Erwa W; Löser R; Witschital K; März W
Int J Clin Pharmacol Ther; 2007 Jun; 45(6):328-34. PubMed ID: 17595890
[TBL] [Abstract][Full Text] [Related]
73. Disposition and sterol-lowering effect of ezetimibe are influenced by single-dose coadministration of rifampin, an inhibitor of multidrug transport proteins.
Oswald S; Giessmann T; Luetjohann D; Wegner D; Rosskopf D; Weitschies W; Siegmund W
Clin Pharmacol Ther; 2006 Nov; 80(5):477-85. PubMed ID: 17112804
[TBL] [Abstract][Full Text] [Related]
74. Acute and Chronic Effects of Rifampin on Letermovir Suggest Transporter Inhibition and Induction Contribute to Letermovir Pharmacokinetics.
Robbins JA; Menzel K; Lassman M; Zhao T; Fancourt C; Chu X; Mostoller K; Witter R; Marceau West R; Stoch SA; McCrea JB; Iwamoto M
Clin Pharmacol Ther; 2022 Mar; 111(3):664-675. PubMed ID: 34888851
[TBL] [Abstract][Full Text] [Related]
75. Pharmacokinetics and bioequivalence study of irbesartan tablets after a single oral dose of 300 mg in healthy Thai volunteers.
Wittayalertpanya S; Chariyavilaskul P; Prompila N; Sayankuldilok N; Eiamart W
Int J Clin Pharmacol Ther; 2014 May; 52(5):431-6. PubMed ID: 24725445
[TBL] [Abstract][Full Text] [Related]
76. Stereoselective analysis of fluvastatin in human plasma for pharmacokinetic studies.
Lanchote VL; Rocha A; de Albuquerque FU; Coelho EB; Bonato PS
J Chromatogr B Biomed Sci Appl; 2001 Dec; 765(1):81-8. PubMed ID: 11817313
[TBL] [Abstract][Full Text] [Related]
77. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.
Mohamed MF; Jungerwirth S; Asatryan A; Jiang P; Othman AA
Br J Clin Pharmacol; 2017 Oct; 83(10):2242-2248. PubMed ID: 28503781
[TBL] [Abstract][Full Text] [Related]
78. Pharmacokinetics and Tolerability of Rufinamide Following Single and Multiple Oral Doses and Effect of Food on Pharmacokinetics in Healthy Chinese Subjects.
Xu M; Ni Y; Zhou Y; He X; Li H; Chen H; Li W
Eur J Drug Metab Pharmacokinet; 2016 Oct; 41(5):541-8. PubMed ID: 26294172
[TBL] [Abstract][Full Text] [Related]
79. The effect of gemfibrozil on the pharmacokinetics of rosuvastatin.
Schneck DW; Birmingham BK; Zalikowski JA; Mitchell PD; Wang Y; Martin PD; Lasseter KC; Brown CD; Windass AS; Raza A
Clin Pharmacol Ther; 2004 May; 75(5):455-63. PubMed ID: 15116058
[TBL] [Abstract][Full Text] [Related]
80. Effects of Strong CYP2C8 or CYP3A Inhibition and CYP3A Induction on the Pharmacokinetics of Brigatinib, an Oral Anaplastic Lymphoma Kinase Inhibitor, in Healthy Volunteers.
Tugnait M; Gupta N; Hanley MJ; Sonnichsen D; Kerstein D; Dorer DJ; Venkatakrishnan K; Narasimhan N
Clin Pharmacol Drug Dev; 2020 Feb; 9(2):214-223. PubMed ID: 31287236
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
